CG0070
- Generic Name
- CG0070
- Drug Type
- Small Molecule
- Background
CG0070 is investigated in clinical trials for treating bladder cancer. CG0070 is a solid. CG0070 can potentially destroy cancer cells by two different mechanisms: direct cell killing by the virus and immune-mediated cell killing stimulated by GM-CSF. CG0070, an oncolytic virus therapy with specificity for multiple cancers, has been evaluated in numerous preclinical studies. It has been engineered to secrete GM-CSF, an immune stimulating hormone, which also serves as the adjuvant in cancer immunotherapy.
- Indication
Investigated for use/treatment in bladder cancer.
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
- Conditions
- High-Risk Non-Muscle-Invasive Bladder Cancer
- Interventions
- First Posted Date
- 2024-08-23
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- CG Oncology, Inc.
- Target Recruit Count
- 325
- Registration Number
- NCT06567743
- Locations
- 🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸Arkansas Urology, Little Rock, Arkansas, United States
🇺🇸Michael G Oefelein, MD Clinical Trials, Bakersfield, California, United States
An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG
- Conditions
- Urothelial CarcinomaBladder CancerNon-Muscle Invasive Bladder CancerUrologic Cancer
- First Posted Date
- 2024-06-05
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- CG Oncology, Inc.
- Registration Number
- NCT06443944
Study of CG0070 After Transurethral Resection in Patients With IR NMIBC
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2025-03-27
- Target Recruit Count
- 20
- Registration Number
- NCT06253845
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
- Conditions
- Urologic CancerNon Muscle Invasive Bladder CancerUrothelial CarcinomaBladder Cancer
- Interventions
- Other: n-dodecyl-B-D-maltoside
- First Posted Date
- 2023-11-01
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- CG Oncology, Inc.
- Target Recruit Count
- 364
- Registration Number
- NCT06111235
- Locations
- 🇺🇸
Urology Centers of Alabama PC, Homewood, Alabama, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC
- Conditions
- Muscle-Invasive Bladder CarcinomaBladder Cancer
- Interventions
- First Posted Date
- 2020-10-30
- Last Posted Date
- 2025-05-06
- Target Recruit Count
- 21
- Registration Number
- NCT04610671
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
- Conditions
- High-grade Ta/ T1 Papillary Disease Bladder CancerNon Muscle Invasive Bladder Cancer
- Interventions
- Other: n-dodecyl-B-D-maltoside
- First Posted Date
- 2020-06-30
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- CG Oncology, Inc.
- Target Recruit Count
- 190
- Registration Number
- NCT04452591
- Locations
- 🇺🇸
Washington University, Saint Louis, Missouri, United States
🇺🇸Specialty Clinical Research of St. Louis, Saint Louis, Missouri, United States
🇺🇸Duke University, Durham, North Carolina, United States
Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin
- Conditions
- Non Muscle Invasive Bladder Cancer
- Interventions
- First Posted Date
- 2020-05-13
- Last Posted Date
- 2022-08-24
- Lead Sponsor
- CG Oncology, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT04387461
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Northwestern University, Tampa, Florida, United States
🇺🇸Johns Hopkins Medical Institution, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.